cN0M0肾细胞癌根治性肾切除术中淋巴结清扫的预后价值
该回顾性研究纳入1109例接受根治性肾切除术的cN0M0期肾细胞癌患者,比较淋巴结清扫(LND)与不清扫的生存差异。经倾向性评分匹配后,LND组与NLND组的5年OS、CSS、PFS均无统计学差异,多因素Cox分析显示LND与OS、CSS、PFS均无关。但pN+是接受LND患者OS、CSS和PFS的独立影响因素,LND可明确病理分期。
要点
- cN0M0肾细胞癌根治性肾切除术中,LND及其程度不带来生存获益。
- pN+是接受LND患者OS、CSS和PFS的独立影响因素。
- LND可明确病理分期,为预后评估及辅助治疗决策提供依据。
核心结论
- LND及其程度不能给行根治性肾切除术治疗的cN0M0期肾细胞癌患者带来生存获益。
- 通过LND能明确病理分期,为预后评估及辅助治疗决策提供关键依据。
研究设计与样本
- 回顾性分析1999年3月至2022年1月中山大学肿瘤防治中心接受根治性肾切除术的肾细胞癌患者1109例。
- 根据是否接受LND分为LND组(512例)和NLND组(597例),采用1∶1倾向性评分匹配(PSM)筛选出各340例。
- 采用Cox回归模型评估LND与OS、CSS、PFS的关系,并评估淋巴结切除数目、扩大LND及淋巴结状态与LND组患者生存的关系。
主要发现
- 512例行LND,中位淋巴结切除数目为4枚,58例接受扩大LND,35例(6.8%)病理淋巴结阳性(pN+)。
- 中位随访77.8个月,1109例中发生复发或转移234例,死亡201例。
- PSM后LND组5年OS、CSS、PFS分别为90.8%、91.7%、82.4%,NLND组分别为89.9%、91.2%、83.7%,差异均无统计学意义(P值分别为0.89、0.56和0.16)。
- 多因素Cox分析显示LND与OS、CSS、PFS均无关(OS:HR=0.97,95% CI:0.66~1.41;CSS:HR=1.03,95% CI:0.67~1.59;PFS:HR=1.16,95% CI:0.82~1.63)。
- 亚组多因素Cox分析显示,在pT3~4期、G3~4级、非透明细胞癌和伴有不良预后病理特征患者中,LND均非OS、CSS和PFS的独立影响因素(均P>0.05)。
关键数值与推荐
- pN+是接受LND的cN0M0期肾细胞癌患者OS的独立影响因素(HR=3.16,95% CI:1.68~5.96)。
- pN+是接受LND的cN0M0期肾细胞癌患者CSS的独立影响因素(HR=3.27,95% CI:1.67~6.39)。
- pN+是接受LND的cN0M0期肾细胞癌患者PFS的独立影响因素(HR=2.23,95% CI:1.30~3.83)。
临床怎么用
- 对cN0M0期肾细胞癌行根治性肾切除术时,不应期望通过LND改善生存。
- LND可用于明确病理分期,pN+结果有助于预后评估和辅助治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the impact of lymph node dissection (LND) and its extent on long-term survival outcomes in patients with cN0M0 renal cell carcinoma (RCC) undergoing radical nephrectomy. Methods: A total of 1 109 patients with RCC who underwent radical nephrectomy at Sun Yat-sen University Cancer Center between March 1999 and January 2022 were retrospectively analyzed. Clinical and pathological data as well as follow-up information were collected. Patients were grouped according to whether LND was performed: the LND group (n=512) and the NLND group (n=597). Propensity score matching (PSM) was applied at a 1∶1 ratio, yielding 340 matched pairs. Cox proportional hazards models were used to evaluate the associations between LND and overall survival (OS), cancer-specific survival (CSS), and progression-free survival (PFS). Among patients who underwent LND, the relationships of the number of removed lymph nodes, extended LND, and lymph-node status with OS, CSS, and PFS were also assessed. Results: Among the 1 109 patients, 512 received LND, with a median of 4 lymph nodes removed. Fifty-eight patients underwent extended LND, and 35 patients (6.8%) were pathologically lymph-node positive (pN+). After a median follow-up of 77.8 months, 234 of the 1 109 patients developed recurrence or metastasis, and 201 died. After PSM, the 5-year OS, CSS, and PFS rates in the LND group were 90.8%, 91.7%, and 82.4%, respectively, compared with 89.9%, 91.2%, and 83.7% in the NLND group, with no statistically significant differences between the two groups (P=0.89, 0.56, and 0.16, respectively). Multivariable Cox analyses showed that LND was not associated with OS, CSS, or PFS in patients with cN0M0 RCC undergoing radical nephrectomy (OS: HR=0.97, 95% CI: 0.66-1.41; CSS: HR=1.03, 95% CI: 0.67-1.59; PFS: HR=1.16, 95% CI: 0.82-1.63). Subgroup multivariable analyses indicated that LND was not an independent prognostic factor for OS, CSS, or PFS among patients with pT3-4 disease, grade G3-4 tumors, non-clear cell RCC, or adverse pathological prognostic features (all P>0.05). Pathological lymph-node positivity was an independent predictor of OS, CSS, and PFS among patients who underwent LND (OS: HR=3.16, 95% CI: 1.68-5.96; CSS: HR=3.27, 95% CI: 1.67-6.39; PFS: HR=2.23, 95% CI: 1.30-3.83). Conclusions: LND and its extent do not confer survival benefits in patients with cN0M0 RCC undergoing radical nephrectomy. However, LND provides accurate pathological staging, which is valuable for prognostic assessment and for guiding decisions regarding adjuvant therapy. 目的: 探讨根治性肾切除术联合淋巴结清扫(LND)及其程度对cN0M0期肾细胞癌患者远期生存的影响。 方法: 1999年3月至2022年1月在中山大学肿瘤防治中心接受根治性肾切除术治疗的肾细胞癌患者1109例,收集其临床病理资料及随访资料。根据是否接受了LND,将患者分为LND组(512例)和NLND组(597例)。采用1∶1倾向性评分匹配(PSM)方法筛选出LND组和NLND组各340例。采用Cox回归模型评估接受LND与否与肾细胞癌患者的总生存时间(OS)、癌症特异性生存时间(CSS)和无进展生存时间(PFS)的关系,评估淋巴结切除数目、是否接受扩大LND及淋巴结状态与LND组患者OS、CSS和PFS的关系。 结果: 1 109例患者中,512例行LND,中位淋巴结切除数目为4枚,58例患者接受了扩大LND,35例(6.8%)病理淋巴结阳性(pN+期)。中位随访77.8个月,1 109例患者中,发生复发或转移234例,死亡201例。PSM后,LND组的5年总体生存率、癌症特异性生存率和无进展生存率分别为90.8%、91.7%和82.4%,NLND组分别为89.9%、91.2%和83.7%,两组比较差异均无统计学意义(P值分别为0.89、0.56和0.16)。多因素Cox回归分析显示,是否接受LND与根治性肾切除治疗cN0M0期肾细胞癌患者的OS、CSS和PFS均无关(OS:HR=0.97,95% CI:0.66~1.41;CSS:HR=1.03,95% CI:0.67~1.59;PFS:HR=1.16,95% CI:0.82~1.63)。亚组的多因素Cox回归分析显示,在pT3~4期患者、G3~4级患者、非透明细胞癌患者和伴有不良预后病理特征患者中,接受LND均非根治性肾切除治疗cN0M0期肾细胞癌患者OS、CSS和PFS的独立影响因素(均P>0.05)。pN+期是接受LND的cN0M0期肾细胞癌患者的OS、CSS和PFS的独立影响因素(OS:HR=3.16,95% CI:1.68~5.96;CSS:HR=3.27,95% CI:1.67~6.39;PFS:HR=2.23,95% CI:1.30~3.83)。 结论: LND及其程度不能给行根治性肾切除术治疗的cN0M0期肾细胞癌患者带来生存获益,但通过LND能明确病理分期,为预后评估及辅助治疗决策提供关键依据。.
引用
- Luo YH, Zou XP, Zhou ZH, et al. [Prognostic value of lymph node dissection in radical nephrectomy for cN0M0 renal cell carcinoma]. Zhonghua Zhong Liu Za Zhi. 2026. PMID: 41688211. doi:10.3760/cma.j.cn112152-20250727-00364
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。